Who are Sofetabart Mipitecan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, Irinotecan, 5FU, leucovorin, aflibercept + FOLFIRI, Fluorouracil Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sofetabart-mipitecan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Sofetabart Mipitecan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sofetabart Mipitecan (Sofetabart Mipitecan) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Folic acid antagonist. Area: Oncology.

phase 3 Folic acid antagonist Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Sofetabart Mipitecan (Sofetabart Mipitecan) — Eli Lilly and Company. Sofetabart Mipitecan is a folic acid antagonist that inhibits thymidylate synthase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sofetabart Mipitecan TARGET	Sofetabart Mipitecan	Eli Lilly and Company	phase 3	Folic acid antagonist	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
Irinotecan, 5FU, leucovorin	Irinotecan, 5FU, leucovorin	Asan Medical Center	marketed	Chemotherapy combination (topoisomerase I inhibitor + antimetabolite)	Topoisomerase I; thymidylate synthase
aflibercept + FOLFIRI	aflibercept + FOLFIRI	CR-CSSS Champlain-Charles-Le Moyne	marketed	VEGF inhibitor (fusion protein) + chemotherapy combination	VEGF-A, VEGF-B, PlGF (aflibercept component); topoisomerase I and thymidylate synthase (FOLFIRI component)
Fluorouracil Injection	Fluorouracil Injection	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	marketed	Antimetabolite	Thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Folic acid antagonist class)

Eli Lilly and Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sofetabart Mipitecan — Competitive Intelligence Brief. https://druglandscape.com/ci/sofetabart-mipitecan. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab